ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 914

A Predictive Model of Disease Outcome in Rituximab-Treated Myositis Patients Using Clinical Features, Autoantibodies, and Serum Biomarkers

Jeannette Olazagasti1, Cynthia S. Crowson2, Molly S. Hein1, Consuelo Lopez de Padilla1, Rohit Aggarwal3, Chester V. Oddis4 and Ann M. Reed1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic, Rochester, MN, 3Medicine, University of Pittsburgh, Pittsburgh, PA, 4Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: autoantibodies, Biomarkers, cytokines, myositis and rituximab

  • Tweet
  • Email
  • Print
Session Information

Session Title: Muscle Biology, Myositis and Myopathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Develop predictive models of early (8 week) and late (24 week) disease outcomes using clinical features, autoantibodies, and serum biomarkers in patients with refractory myositis treated with rituximab.

Methods: In the Rituximab in Myositis (RIM) trial, all subjects (76 with adult dermatomyositis, 76 with adult polymyositis and 48 with juvenile dermatomyositis) received rituximab (2 doses on consecutive weeks) with half the patients receiving drug at baseline and half receiving drug 8 weeks later. Using start of treatment as baseline, serum samples (n=177) were analyzed at baseline and after 8 and 24 weeks after rituximab. Potential predictors included the following baseline factors: clinical features, serum muscle enzymes, interferon gene score, autoantibodies (anti-synthetase n=28, TIF1-g n=19, Mi-2 n=25, SRP n=21, NXP2 n=18, non-myositis associated n=24, undefined autoantibody n=9), and cytokines/chemokines measured by multiplexed sandwich immunoassays (Meso Scale Discovery) (type-1 IFN-inducible [IP-10, I-TAC, MCP1], Th1 [IFNγ, TNFα, IL2], Th2 [IL4, IL5, IL10, IL12, IL13], Th17 [IL6, IL17, IL1β] and regulatory cytokines [IL10, TNFa, MIP-1α, MIP-1β]). Our primary definition of response to treatment was based on absolute change from baseline to 8 weeks and 24 weeks in physician global visual analog scale (VAS), muscle VAS, and extramuscular VAS. Multivariable linear regression models were developed using stepwise variable selection methods.

Results: Preliminary models were built with good predictive ability both for change in physician global assessment and muscle disease activity at 24 weeks (R-square=0.41 and 0.40, respectively). The model for change in physician global assessment included the following baseline clinical and lab features: muscle disease activity, physician global assessment, and I-TAC (Table). The model for change in muscle disease activity included baseline physician global assessment, skeletal disease activity, I-TAC and IFNγ. Similarly, a predictive model was built with excellent predictive ability (R-square=0.67) for change in extramuscular disease activity at 24 weeks. This model included the following baseline clinical and lab features: constitutional, skeletal and extramuscular disease activity by VAS, and MIP-1β and Mi-2. We also built models from baseline to 8 weeks but their predictive ability was inferior compared to those for 24 weeks (R-square<0.3).

Conclusion: Changes in disease activity over time following treatment with rituximab in patients with refractory myositis can be predicted.  These models could be clinically useful to optimize treatment selection in these patients.

Outcomes ->

Change in Physician Global VAS

Change in Muscle VAS

Change in Extramuscular VAS

Predictors (baseline)

Coefficient

P-value

Coefficient

P-value

Coefficient

P-value

Physician Global Assessment

-0.80

0.0007

-0.33

0.002

—

—

Muscle Disease Activity

0.51

0.0008

—

—

—

—

Extramuscular Global Assessment

—

—

—

—

0.60

0.0002

Skeletal Disease Activity

—

—

0.38

0.02

0.26

0.04

Constitutional Disease Activity

—

—

—

—

0.23

0.02

Mi-2

—

—

—

—

-15.47

0.002

I-TAC

-0.01

0.025

-0.02

0.01

—

—

IFNγ

—

—

-0.35

0.01

—

—

MIP-1β

—

—

—

—

0.008

<0.0001


Disclosure:

J. Olazagasti,
None;

C. S. Crowson,
None;

M. S. Hein,
None;

C. Lopez de Padilla,
None;

R. Aggarwal,

Questcor,

2,

Questcor,

5;

C. V. Oddis,

Novartis Pharmaceutical Corporation,

5;

A. M. Reed,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-predictive-model-of-disease-outcome-in-rituximab-treated-myositis-patients-using-clinical-features-autoantibodies-and-serum-biomarkers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies